<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098328</url>
  </required_header>
  <id_info>
    <org_study_id>201901</org_study_id>
    <nct_id>NCT04098328</nct_id>
  </id_info>
  <brief_title>Early Feasibility EXperience of Posterior Leaflet RestOration to REduce Mitral Regurgitation</brief_title>
  <acronym>EXPLORE MR</acronym>
  <official_title>Early Feasibility EXperience of Posterior Leaflet RestOration to REduce Mitral Regurgitation (EXPLORE MR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polares Medical SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polares Medical SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early feasibility study, single-arm registry design&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First-In-Human&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement from baseline mitral regurgitation</measure>
    <time_frame>30 days</time_frame>
    <description>Grade 2+ or less as evaluated by 2D transthoracic echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success according to MVARC2 criteria</measure>
    <time_frame>24 hours</time_frame>
    <description>Absence of procedure mortality&#xD;
Successful access, delivery and retrieval of investigation delivery system&#xD;
Successful deployment and correct positioning of intended implant(s)&#xD;
Freedom from emergency surgery/re-intervention related to device or access procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success according to MVARC2 criteria</measure>
    <time_frame>30 days</time_frame>
    <description>Absence of procedure mortality or stroke&#xD;
Proper placement and positioning of device&#xD;
Freedom from unplanned re-intervention related to device or access procedure&#xD;
Continued intended safety and performance of the device:&#xD;
No evidence of structural or functional failure&#xD;
No device technical failure issues/complications&#xD;
MR reduction to moderate or less without stenosis&#xD;
Absence of major device or procedure-related SAE:&#xD;
Death&#xD;
Stroke&#xD;
Life-threatening bleed&#xD;
Major vascular complication&#xD;
Major cardiac structural complication&#xD;
No device technical failure issues/complications&#xD;
Stage 2 or 3 AKI&#xD;
MI or coronary ischemia requiring PCI or CABG&#xD;
Shock, heart or respiratory failure requiring IV vasopressors, mechanical intervention or prolonged intubation&#xD;
Valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success according to MVARC2 criteria</measure>
    <time_frame>30 days, 6 and 12 months, and 2 - 5 years post treatment</time_frame>
    <description>Absence of procedure mortality or stroke&#xD;
Proper placement and positioning of device&#xD;
Freedom from unplanned re-intervention related to device or access procedure&#xD;
Continued intended safety and performance of the device:&#xD;
No evidence of structural or functional failure&#xD;
No device technical failure issues/complications&#xD;
MR reduction to moderate or less without stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient success according to MVARC2 criteria</measure>
    <time_frame>30 days, 6 and 12 months, and 2 - 5 years post treatment</time_frame>
    <description>Device success&#xD;
Patient returned to pre-procedure setting&#xD;
No rehospitalization or reintervention for mitral regurgitation or heart failure&#xD;
Functional improvement from baseline by one or more NYHA class&#xD;
6MWT improvement from baseline by 50 metres or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate (%) of major adverse events as defined by MVARC2 criteria</measure>
    <time_frame>Procedure, discharge/7 days, 30 days, 6 and 12 months, and 2 - 5 years post treatment</time_frame>
    <description>All-cause mortality, hospitalization due to cardiac conditions, stroke or TIA, myocardial infarction, access site and vascular complications, bleeding complications, acute kidney injury up to 7 days post-procedure, and arrhythmias and conduction system disturbances</description>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Valve Disease</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Inoperable or high surgical risk patients with symptomatic degenerative or functional&#xD;
        mitral regurgitation (Grade 3+ or higher) with mitral valve anatomy deemed unsuitable, or&#xD;
        off-label, to be treated with an approved edge-to-edge repair system.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older.&#xD;
&#xD;
          2. Greater than moderate degenerative or functional mitral regurgitation (Grade 3+ or&#xD;
             higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to&#xD;
             study procedure&#xD;
&#xD;
          3. Patient must present with an STS Score less than 10%&#xD;
&#xD;
          4. High surgical risk for conventional mitral repair or replacement due to morphological&#xD;
             criteria (e.g. leaflet or annulus calcifications) as assessed by the local heart team&#xD;
             comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist&#xD;
             experienced in treating mitral valve disease and heart failure&#xD;
&#xD;
          5. Mitral valve anatomy deemed unsuitable to be treated with an approved edge-to-edge&#xD;
             repair system (e.g., retracted posterior leaflet, lack of leaflet tissue, calcified or&#xD;
             cleft posterior leaflet) as assessed by the local heart team comprised of a cardiac&#xD;
             surgeon experienced in mitral valve surgery and a cardiologist experienced in treating&#xD;
             mitral valve disease and heart failure&#xD;
&#xD;
          6. Patient is approved by an independent Patient Eligibility Committee&#xD;
&#xD;
          7. New York Heart Association (NYHA) Functional Class III or IV&#xD;
&#xD;
          8. Patient willing to participate in study and provide signed EC-approved informed&#xD;
             consent.&#xD;
&#xD;
          9. Treating physician and patient agree that patient is able to return for all required&#xD;
             post- procedure follow-up visits&#xD;
&#xD;
         10. Women of child-bearing potential have a negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe tricuspid regurgitation&#xD;
&#xD;
          2. Severe aortic stenosis or insufficiency&#xD;
&#xD;
          3. Severe mitral annulus calcification&#xD;
&#xD;
          4. Diseased mitral anterior leaflet such as flail / prolapse/ heavy calcification&#xD;
&#xD;
          5. Implanted vena cava filter&#xD;
&#xD;
          6. Femoral veins with severe angulation and calcification&#xD;
&#xD;
          7. Contraindication for transesophageal echocardiography (TEE) or MDCT scan.&#xD;
&#xD;
          8. Active infection or endocarditis&#xD;
&#xD;
          9. Previous mitral valve surgery&#xD;
&#xD;
         10. Prior orthotopic heart transplantation&#xD;
&#xD;
         11. Pulmonary artery systolic hypertension &gt; 70mmHg&#xD;
&#xD;
         12. Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus&#xD;
&#xD;
         13. Left ventricular ejection fraction (LVEF) &lt; 30%&#xD;
&#xD;
         14. Implant or revision of any pacing device &lt; 30 days prior to intervention&#xD;
&#xD;
         15. Symptomatic coronary artery disease treated &lt; 30 days prior to study procedure&#xD;
&#xD;
         16. Myocardial infarction requiring intervention &lt; 30 days prior to study procedure&#xD;
&#xD;
         17. Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis),&#xD;
             hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis&#xD;
&#xD;
         18. Active peptic ulcer or upper gastrointestinal bleeding &lt; 90 days prior to study&#xD;
             procedure&#xD;
&#xD;
         19. Stroke &lt; 180 days prior to study procedure&#xD;
&#xD;
         20. Severe renal insufficiency (creatinine &gt; 3.0 mg/dL) or patient requiring dialysis&#xD;
&#xD;
         21. Cardiogenic shock at time of enrolment&#xD;
&#xD;
         22. Hemodynamic instability requiring inotropic support or mechanical heart assistance&#xD;
&#xD;
         23. Concurrent medical condition with a life expectancy of less than 2 years&#xD;
&#xD;
         24. Pregnancy at time of enrolment&#xD;
&#xD;
         25. History of bleeding diathesis or coagulopathy or leukopenia (WBC &lt; 3,000 mcL) or acute&#xD;
             anemia (Hb &lt; 9 g/dL) or thrombocytopenia (platelets &lt; 50,000 cells mcL)&#xD;
&#xD;
         26. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or&#xD;
             clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be&#xD;
             pre-medicated&#xD;
&#xD;
         27. Severe dementia or lack of capacity due to conditions that result in either inability&#xD;
             to provide informed consent for the trial/procedure, prevent independent lifestyle&#xD;
             outside of a chronic care facility, or will fundamentally complicate rehabilitation&#xD;
             from the procedure or compliance with follow-up assessments&#xD;
&#xD;
         28. Emergency situations&#xD;
&#xD;
         29. Company employees or their immediate family members&#xD;
&#xD;
         30. Patient is under guardianship&#xD;
&#xD;
         31. Patient is participating in another clinical study for which follow-up is currently&#xD;
             ongoing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura A Brenton</last_name>
    <role>Study Director</role>
    <affiliation>Polares Medical</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Schaefer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MarienKrankenhaus &amp; Asklepios Klinik St. Georg, Hamburg (DE)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Windecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital Bern, Bern (CH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura A Brenton</last_name>
    <phone>+1 313 919 8044</phone>
    <email>lbrenton@polaresmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helge Moellmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien Praz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Toggweiler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

